190 related articles for article (PubMed ID: 21909311)
1. A literature review of cost-benefit analyses for the treatment of alcohol dependence.
Popova S; Mohapatra S; Patra J; Duhig A; Rehm J
Int J Environ Res Public Health; 2011 Aug; 8(8):3351-64. PubMed ID: 21909311
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients.
Annemans L; Vanoverbeke N; Tecco J; D'Hooghe D
Eur Addict Res; 2000 Jun; 6(2):71-8. PubMed ID: 10899732
[TBL] [Abstract][Full Text] [Related]
3. Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
Schwappach D; Popova S; Mohapatra S; Patra J; Godinho A; Rehm J
Drug Alcohol Depend; 2012 May; 122(3):165-73. PubMed ID: 21924845
[TBL] [Abstract][Full Text] [Related]
4. Acamprosate. Pharmacoeconomic implications of therapy.
Foster RH; McClellan KJ
Pharmacoeconomics; 1999 Dec; 16(6):743-55. PubMed ID: 10724798
[TBL] [Abstract][Full Text] [Related]
5. A critical review of pharmacoeconomic studies of acamprosate.
Poldrugo F; Haeger DA; Comte S; Walburg J; Palmer AJ
Alcohol Alcohol; 2005; 40(5):422-30. PubMed ID: 15939706
[TBL] [Abstract][Full Text] [Related]
6. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
7. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.
Palmer AJ; Neeser K; Weiss C; Brandt A; Comte S; Fox M
Alcohol Alcohol; 2000; 35(5):478-92. PubMed ID: 11022023
[TBL] [Abstract][Full Text] [Related]
8. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study.
Schädlich PK; Brecht JG
Pharmacoeconomics; 1998 Jun; 13(6):719-30. PubMed ID: 10179707
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients.
Rychlik R; Siedentop H; Pfeil T; Daniel D
Eur Addict Res; 2003 Apr; 9(2):59-64. PubMed ID: 12644731
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant drug treatment of alcoholism with acamprosate: between sectoral budgets and disease management].
Rychlik R; Paschen B; Kirchhoff D; Daniel D; Pfeil T; Kilburg A
Dtsch Med Wochenschr; 2001 Aug; 126(33):899-904. PubMed ID: 11514924
[TBL] [Abstract][Full Text] [Related]
11. New pharmacotherapies for alcohol dependence: are they being used and what do they cost?
Doran CM; Fawcett JE; Shakeshaft AP; Shanahan MD; Mattick RP
Med J Aust; 2003 Aug; 179(4):218. PubMed ID: 12914502
[No Abstract] [Full Text] [Related]
12. Acamprosate for the adjunctive treatment of alcohol dependence.
Overman GP; Teter CJ; Guthrie SK
Ann Pharmacother; 2003; 37(7-8):1090-9. PubMed ID: 12841823
[TBL] [Abstract][Full Text] [Related]
13. Measuring economic outcomes of alcohol treatment using the Economic Form 90.
Bray JW; Zarkin GA; Miller WR; Mitra D; Kivlahan DR; Martin DJ; Couper DJ; Cisler RA
J Stud Alcohol Drugs; 2007 Mar; 68(2):248-55. PubMed ID: 17286343
[TBL] [Abstract][Full Text] [Related]
14. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients.
Zarkin GA; Bray JW; Aldridge A; Mitra D; Mills MJ; Couper DJ; Cisler RA;
Arch Gen Psychiatry; 2008 Oct; 65(10):1214-21. PubMed ID: 18838638
[TBL] [Abstract][Full Text] [Related]
15. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
Gastfriend DR
Ann N Y Acad Sci; 2014 Oct; 1327(1):112-30. PubMed ID: 25236185
[TBL] [Abstract][Full Text] [Related]
16. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the cost-effectiveness of the COMBINE study for alcohol dependent patients: the patient perspective.
Dunlap LJ; Zarkin GA; Bray JW; Mills M; Kivlahan DR; McKay JR; Latham P; Tonigan JS
Med Care; 2010 Apr; 48(4):306-13. PubMed ID: 20355261
[TBL] [Abstract][Full Text] [Related]
18. The current situation of treatment systems for alcoholism in Korea.
Kim JW; Lee BC; Kang TC; Choi IG
J Korean Med Sci; 2013 Feb; 28(2):181-9. PubMed ID: 23400047
[TBL] [Abstract][Full Text] [Related]
19. New pharmacotherapies for alcohol dependence.
Graham R; Wodak AD; Whelan G
Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
[TBL] [Abstract][Full Text] [Related]
20. The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Brodtkorb TH; Bell M; Irving AH; Laramée P
CNS Drugs; 2016 Feb; 30(2):163-77. PubMed ID: 26879458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
